N/A
N=60
Conscious Sedation for Epilepsy Surgery
Epilepsy
Bottom Line
View on ClinicalTrials.gov: NCT02988050 ↗Enrolled (actual)
60
Serious AEs
0.0%
Results posted
Oct 2020
Primary outcome: Primary: Patients Satisfaction — 6.33; 6.45 score on a scale
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Remifentanil (Drug); Dexmedetomidine (Drug); Propofol (Drug); Bupivacaine (Drug); Lidocaine (Drug); Epinephrine (Drug)
- Age
- Adult · 18+ yrs
- Sex
- All
- Sponsor
- Menoufia University
- Primary completion
- Feb 2016
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Patients Satisfaction |
6.33; 6.45 | — |
Summary
Sixty patients were randomly allocated into two groups, group PD and group PR, thirty patients in each group. Patients in PD group received propofol and dexmedetomidine intravenous infusion and patients in PR group received propofol and remifentanil intravenous infusion. Sedation score and patients' satisfaction, surgeon satisfaction, heart rate, mean arterial blood pressure, oxygen saturation, and side effects such as respiratory depression, nausea, vomiting, airway obstruction, and oxygen desaturation were recorded.
Eligibility Criteria
Inclusion Criteria
- Patients require conscious sedation for epilepsy surgery
Exclusion Criteria
- Patients refusal, allergy to drugs used, and uncooperative patients.
Data sourced from ClinicalTrials.gov (NCT02988050). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.